Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Biomarkers in renal cancer.

Moch H, Srigley J, Delahunt B, Montironi R, Egevad L, Tan PH.

Virchows Arch. 2014 Mar;464(3):359-65. doi: 10.1007/s00428-014-1546-1. Epub 2014 Feb 1. Review.

PMID:
24487793
[PubMed - indexed for MEDLINE]
2.

[Renal cancer biomarkers. What is justified?].

Moch H.

Pathologe. 2012 Nov;33 Suppl 2:278-81. doi: 10.1007/s00292-012-1683-8. Review. German.

PMID:
23052348
[PubMed - indexed for MEDLINE]
3.

Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference.

Reuter VE, Argani P, Zhou M, Delahunt B; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group.

Am J Surg Pathol. 2014 Aug;38(8):e35-49. doi: 10.1097/PAS.0000000000000258.

PMID:
25025368
[PubMed - indexed for MEDLINE]
4.

Renal tumors: diagnostic and prognostic biomarkers.

Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel.

Am J Surg Pathol. 2013 Oct;37(10):1518-31. doi: 10.1097/PAS.0b013e318299f12e.

PMID:
24025522
[PubMed - indexed for MEDLINE]
5.

Prognostic biomarkers in renal cell carcinoma.

Jiang Z.

Expert Rev Mol Diagn. 2007 May;7(3):293-307. Review.

PMID:
17489736
[PubMed - indexed for MEDLINE]
6.

Gene array studies in renal neoplasia.

Higgins JP.

ScientificWorldJournal. 2006 Apr 26;6:502-11. Review.

PMID:
16648909
[PubMed - indexed for MEDLINE]
Free Article
7.

Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS.

J Urol. 2005 Jun;173(6):1853-62. Review.

PMID:
15879764
[PubMed - indexed for MEDLINE]
8.

The role of molecular markers in the staging of renal cell carcinoma.

Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS.

BJU Int. 2007 May;99(5 Pt B):1208-11. Review. No abstract available.

PMID:
17441912
[PubMed - indexed for MEDLINE]
9.

Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens.

Kench JG, Clouston DR, Delprado W, Eade T, Ellis D, Horvath LG, Samaratunga H, Stahl J, Stapleton AM, Egevad L, Srigley JR, Delahunt B.

Pathology. 2011 Aug;43(5):410-9. doi: 10.1097/PAT.0b013e328348a6b3. Review.

PMID:
21716159
[PubMed - indexed for MEDLINE]
10.

[Molecular characterization of metastatic renal cell carcinomas. Differentiation of prognosis and therapy].

Junker K, Sanjmyatav J, Heinze C, Walter M, Heinzelmann J, Wunderlich H, Schubert J, Steiner T.

Urologe A. 2008 Sep;47(9):1187-9. doi: 10.1007/s00120-008-1847-6. German.

PMID:
18688592
[PubMed - indexed for MEDLINE]
11.

Proteomics and the search for biomarkers for renal cancer.

Craven RA, Vasudev NS, Banks RE.

Clin Biochem. 2013 Apr;46(6):456-65. doi: 10.1016/j.clinbiochem.2012.11.029. Epub 2012 Dec 7. Review.

PMID:
23228867
[PubMed - indexed for MEDLINE]
12.

Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.

Hornsby CD, Cohen C, Amin MB, Picken MM, Lawson D, Yin-Goen Q, Young AN.

Arch Pathol Lab Med. 2007 Oct;131(10):1541-6.

PMID:
17922590
[PubMed - indexed for MEDLINE]
13.

Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations.

Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, Samaratunga H, Tamboli P, Delahunt B, Egevad L, Montironi R, Srigley JR; members of the ISUP Renal Tumor Panel.

Am J Surg Pathol. 2013 Oct;37(10):1505-17. doi: 10.1097/PAS.0b013e31829a85d0.

PMID:
24025521
[PubMed - indexed for MEDLINE]
14.

Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.

Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG Jr, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L.

Cancer. 2009 May 15;115(10 Suppl):2247-51. doi: 10.1002/cncr.24229.

PMID:
19402064
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy.

Cheng L, Williamson SR, Zhang S, Maclennan GT, Montironi R, Lopez-Beltran A.

Expert Rev Anticancer Ther. 2010 Jun;10(6):843-64. doi: 10.1586/era.10.72. Review.

PMID:
20553210
[PubMed - indexed for MEDLINE]
16.

Prognostic markers in renal cell carcinoma.

Ljungberg B.

Curr Opin Urol. 2007 Sep;17(5):303-8. Review.

PMID:
17762621
[PubMed - indexed for MEDLINE]
17.

Prognostic factors in renal cell carcinoma.

Shuch BM, Lam JS, Belldegrun AS, Figlin RA.

Semin Oncol. 2006 Oct;33(5):563-75. Review.

PMID:
17045085
[PubMed - indexed for MEDLINE]
18.

Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.

Kusuda Y, Miyake H, Behnsawy HM, Fukuhara T, Inoue TA, Fujisawa M.

Urol Oncol. 2013 Jan;31(1):42-50. doi: 10.1016/j.urolonc.2010.09.008. Epub 2011 Mar 10.

PMID:
21396851
[PubMed - indexed for MEDLINE]
19.

Distribution of subtypes of metastatic renal-cell carcinoma: correlating findings of fine-needle aspiration biopsy and surgical pathology.

Mai KT, Alhalouly T, Lamba M, Yazdi HM, Stinson WA.

Diagn Cytopathol. 2003 Feb;28(2):66-70.

PMID:
12561022
[PubMed - indexed for MEDLINE]
20.

Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?

Rouvière O, Bouvier R, Négrier S, Badet L, Lyonnet D.

Nat Clin Pract Oncol. 2006 Apr;3(4):200-13. Review.

PMID:
16596144
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk